Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-706 in Advanced Solid Tumors
NCT05599984Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2022
- Primary completion
- Nov 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 10
01
Overview
Phase 1, randomised, open-label trial of turmetabart adizutecan in solid tumor (advanced stage), small cell lung cancer (SCLC), central nervous system tumor and 1 more (6 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants With Adverse Events, Maximum Observed Serum/Plasma Concentration of ABBV-706 and 11 more. Started Dec 2022; status: active, not recruiting.
02
Drugs
turmetabart adizutecan
03
Conditions
solid tumor (advanced stage)small cell lung cancer (SCLC)central nervous system tumorneuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT05599984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05599984.